Osiris Therapeutics (OSIR) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Osiris Therapeutics (OSIR) PR Raised to $26 at Piper Jaffray
November 10, 2014 7:02 AM ESTPiper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and boosted his price target on Osiris Therapeutics (NASDAQ: OSIR) to $26.00 (from $23.50) following strong Grafix sales.
Tenthoff commented, "Osiris reported BioSurgery sales of $17.2 million in 3Q:14, up 29% sequentially, and above our $14... More
